TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05155761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe® Monitor
Description: Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days.
Study: NCT05354895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial infrared laser stimulation
Description: non-invasive, non-pharmacologic photobiomodulation device
Study: NCT06139328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 765845
Description: Placebo matching BI 765845
Study: NCT06138470

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron extract
Description: Food supplements are taken during 6 weeks by healthy volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Scutellaria baicalensis extract
Description: Food supplements are taken during 6 weeks by healthy volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron and Scutellaria baicalensis extract
Description: Food supplements are taken during 6 weeks by healthy volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study: NCT06237166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mylovia
Description: Participants will receive access to the digital health intervention mylovia in addition to TAU.
Study: NCT05995496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting state
Description: 16 hours of fasting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting state
Description: 16 hours of fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed state
Description: Fed a standardized meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fed state
Description: Fed a standardized meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Neuroimaging with computational modeling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Neuroimaging with computational modeling
Study: NCT06517277

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
Study: NCT06417476

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Formate
Description: 400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study: NCT05450601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2106-1
Description: Take once daily for 2 weeks orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2103-1
Description: Placebo drug. Take once daily for 2 weeks orally
Study: NCT06417476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Formate
Description: 400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study: NCT05705778

Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.

Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.

Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.
Study: NCT06365853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricating Eye Drops
Description: Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricating Eye Drops
Description: Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate ophthalmic suspension 1% eye drops
Description: Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution eye drops
Description: Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
Study: NCT04967248

Intervention type: OTHER
Intervention: Alpelisib
Description: Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.

Intervention type: OTHER
Intervention: Fulvestrant
Description: Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
Study: NCT05077605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional residual capacity measure by electrical impedance tomography
Description: Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
Study: NCT05438407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
Study: NCT05827081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg orally once daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ansastrozole
Description: Anastrozole 1 mg orally once daily continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg once daily continuously
Study: NCT05525013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin Powder
Description: Simvastatin gel placed as an intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Calcium hydroxide intracanal medication
Study: NCT06492291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral tablet
Study: NCT05836584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT05705778

Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.

Intervention type: PROCEDURE
Intervention: standard amblyopia treatment
Description: amblyopia treatment following international guidelines and genetic tests.
Study: NCT06417476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
Study: NCT05836584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study: NCT05450601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2106-2
Description: Take once daily for 6 weeks orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2103-2
Description: Placebo drug. Take once daily for 6 weeks orally
Study: NCT05836584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT05005845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX-179 gel
Description: NFX-179 topical gel is the active investigational product being studied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX-179 gel
Description: NFX-179 topical gel is the active investigational product being studied

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: NFX-179 vehicle gel is the placebo comparator for this study
Study: NCT05836584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT06417476

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation
Description: The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
Study: NCT05836584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT05836584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT04527991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Administered intravenously
Study: NCT06455449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (blinded)
Description: Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo delivered subcutaneously, once weekly for 52 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (unblinded, open label)
Description: At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
Study: NCT06460506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration
Study: NCT04587843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave 8Mg-90Mg Extended-Release Tablet
Description: Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
Study: NCT05870150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhimurium
Description: Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhimurium
Description: Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
Study: NCT04700345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx
Description: Embolization of the Middle Meningeal Artery using the liquid embolic material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burr-hole
Description: Burr-hole drainage of subdural hematoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burr-hole
Description: Burr-hole drainage of subdural hematoma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: best medical management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: best medical management
Study: NCT06423495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity laser treatment
Description: The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
Study: NCT05475210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE
Description: Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Solution
Description: The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Study: NCT03852992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Laser Minoxidil 2%
Description: 2ml of 20mg/ml sterile solution, applied post-laser procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Laser Minoxidil 2%
Description: 2ml of 20mg/ml sterile solution, applied post-laser procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At-Home Minoxidil 5%
Description: 2ml of 50mg/ml foam q24 h for duration of study

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser
Description: Fractional ablative, deep mode, 5% fractional coverage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Fractional ablative, deep mode, 5% fractional coverage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 5mg minoxidil
Description: 0.25ml of 20mg/ml sterile solution, applied post-laser procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 10mg minoxidil
Description: 0.5ml of 20mg/ml sterile solution, applied post-laser procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-laser 20mg minoxidil
Description: 1ml of 20mg/ml sterile solution, applied post-laser procedure
Study: NCT06578624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA53-OS (phase 1)
Description: Dose escalation phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years. Single participant cohorts will be enrolled until a Grade 2 or greater toxicity is observed and then 3+3 multi-participant cohorts will be enrolled until the MTD is identified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA53-OS (phase 2)
Description: Dose expansion phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years at the MTD identified in phase 1.
Study: NCT06577116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK006 IV
Description: Formulation for intravenous infusion
Study: NCT06267924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband Experimental
Description: Participants will be randomly assigned to use the Otoband Experimental device to determine effectiveness in providing temporary relief to symptoms of vertigo.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Otoband Sham
Description: Participants will be randomly assigned to use the Otoband Sham device to determine effectiveness in providing temporary relief to symptoms of vertigo.
Study: NCT06462235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: ATM-AVI Single Dose, Cohorts 1-4
Description: Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Description: Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
Study: NCT06337318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT scan
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT06337318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT05513560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: 10mg pills, 2 pills twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg pill 3 times per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
Study: NCT06649019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1 for Astigmatism (DT1fA)
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1 for Astigmatism (DT1fA)
Description: Control Lens